0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
CLINICAL SYNTHESIS   |    
Comment on Guideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition
Robert M.A. Hirschfeld, M.D.
FOCUS 2007;5:33-33.
View Author and Article Information

Comments On Clinically Important Studies Published Since The Bipolar Watch Was Published In November 2005.

CME Disclosure
Robert M.A. Hirschfield, M.D., Titus H. Harris Chair; Harry K. Davis Professor, Professor and Chairperson, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX.

Consultant/advisory board: Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Jazz Pharmaceutical, KV Pharmaceutical, Ortho McNeil, Eli Lilly & Company, Novartis, Organon, Inc., Pfizer, Inc., Shire, Solvay Pharmaceuticals, UCB Pharma, Wyeth-Ayerst.

Copyright 2007 American Psychiatric Association

In the year since publication of the Watch, the results of several clinically important studies have been published. The efficacy of aripiprazole (1) and divalproex extended release (2) in the acute treatment of mania were each demonstrated compared to placebo. Olanzapine and risperidone monotherapy were equivalent in the acute treatment of mania (3). The efficacy of quetiapine in the acute treatment of bipolar depression was confirmed in a second study (4), and the drug has received FDA approval for the treatment of bipolar depression. The olanzapine/fluoxetine combination was found to be superior in efficacy compared to lamotrigine, but had considerably more side effects (5). Both aripiprazole (6) and olanzapine (7) were found to be superior to placebo in maintenance therapy. Several studies have supported the use of cognitive behavioral therapy or systematic psychoeducation to prolong remission (810).

Sachs et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of Psychopharmacology. Psychopharmacol  2006; 20(4): 536—546
[CrossRef]
 
Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M; Depakote ER Mania Study Group. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psyc  2006; 67(10):1501
[CrossRef]
 
Perlis RH et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry  2006; 67(11):1747—1753
[PubMed]
[CrossRef]
 
Thase et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol  2006; 26(6):600—609
[PubMed]
[CrossRef]
 
Brown et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry  2006; 67(7):1025—1033
[PubMed]
[CrossRef]
 
Keck et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry  2006; 67(4):626—637
[PubMed]
[CrossRef]
 
Tohen et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with Bipolar I Disorder responding to acute treatment with olanzapine. Am J Psychiatry  2006; 163:247—256
[PubMed]
[CrossRef]
 
Lam et al. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry  2005; 162:324—329
[PubMed]
[CrossRef]
 
Simon et al. Randomized trial of a population-based care program for people with bipolar disorder. Psychological Medicine  2005; 35:13—24
[PubMed]
 
Ball et al. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psych  2006; 67:277—286
[CrossRef]
 
+

References

Sachs et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of Psychopharmacology. Psychopharmacol  2006; 20(4): 536—546
[CrossRef]
 
Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M; Depakote ER Mania Study Group. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psyc  2006; 67(10):1501
[CrossRef]
 
Perlis RH et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry  2006; 67(11):1747—1753
[PubMed]
[CrossRef]
 
Thase et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol  2006; 26(6):600—609
[PubMed]
[CrossRef]
 
Brown et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry  2006; 67(7):1025—1033
[PubMed]
[CrossRef]
 
Keck et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry  2006; 67(4):626—637
[PubMed]
[CrossRef]
 
Tohen et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with Bipolar I Disorder responding to acute treatment with olanzapine. Am J Psychiatry  2006; 163:247—256
[PubMed]
[CrossRef]
 
Lam et al. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry  2005; 162:324—329
[PubMed]
[CrossRef]
 
Simon et al. Randomized trial of a population-based care program for people with bipolar disorder. Psychological Medicine  2005; 35:13—24
[PubMed]
 
Ball et al. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psych  2006; 67:277—286
[CrossRef]
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
APA Practice Guidelines > Chapter 7.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 54.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 44.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 11.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles